Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018

March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a...

Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger 

News | ACC | March 20, 2018

March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the...

Reducing Co-Payments Improves Patient and Physician Adherence to Guideline-Recommended Treatment Post-Heart Attack, late-breaking trial at ACC.18.

Image from presentation, "Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study," Wang 

News | ACC | March 20, 2018

March 20, 2018 — When patients who had a heart attack were given vouchers to cover their co-payments for...

Personalized Approach to Selecting Antiplatelet Drugs Improves Outcomes

Image from presentation, "The PHARMCLO Study," Diego Ardissino, M.D., F.A.C.C. 

News | ACC | March 20, 2018

March 20, 2018 — Patients with acute coronary syndrome experienced a substantially lower rate of heart attack,...

Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care
News | ACC | March 20, 2018

March 20, 2018 — A pill combining low doses of three...

Managing Blood Pressure in Barbershops Yields Substantial Improvements

Image from presentation, "A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops," Victor et al

News | ACC | March 20, 2018

March 20, 2018 — African-American men who received medical intervention aimed at controlling their...

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018

March 19, 2018 — The combined rate of death from any cause, heart attack or stroke within 18 months was not...

Aspirin Lowers Risk of Death for Patients with Diabetes, Heart Failure
News | ACC | March 15, 2018

March 15, 2018 — For people living with both Type 2 diabetes and heart failure, taking an...

The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018

March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of...

Beta Blocker Shows Mixed Results in Protecting Against Chemo-Induced Heart Damage
News | Cardio-oncology | March 14, 2018

March 14, 2018 — After six months of follow-up, women newly diagnosed with...

Alirocumab Reduces Cardiovascular Events after Acute Coronary Syndrome
News | ACC | March 13, 2018

March 13, 2018 –  Among patients with persistently high cholesterol despite high-intensity statin therapy, the...

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018

February 13, 2018 — Abbott announced the first patient has been enrolled in a...

Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018

February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the...

Overlay Init